Previous close | 1.3300 |
Open | 1.3300 |
Bid | 0.9000 |
Ask | 2.5500 |
Strike | 195.00 |
Expiry date | 2025-01-17 |
Day's range | 1.3300 - 1.3300 |
Contract range | N/A |
Volume | |
Open interest | 327 |
On May 16, 2024, Rainer Blair, President & CEO of Danaher Corp (NYSE:DHR), executed a sale of 9,005 shares of the company.
Danaher (DHR) gains from strength in academic and applied markets, Abcam buyout and pro-investor policies. However, softness in its Biotechnology unit is concerning.
Danaher Corporation (NYSE: DHR), a global science and technology innovator ("Danaher"), today launched a collaboration with Johns Hopkins University aiming to develop new methods for diagnosing mild TBI. As part of the Danaher Beacons program, researchers at Johns Hopkins University will leverage technology from Beckman Coulter Diagnostics, a Danaher subsidiary and leader in clinical diagnostics, to potentially establish correlations between a new biomarker panel and clinical outcomes.